Pharmacovigilance Industry Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related safety problems, as defined by the World Health Organization and echoed by regulatory bodies such as the European Medicines Agency. The global PV market covers a wide range of services, from case processing and signal detection to risk management planning, regulatory reporting, and safety database management. With a market size of roughly $9.18 billion in 2025, the industry supports pharmaceutical companies, biotechnology firms, and contract research organizations in meeting their global safety obligations.

• •Encompasses safety signal detection, adverse event case processing, regulatory reporting, and risk management
• •Supports every stage of a drug's lifecycle, from clinical trials through post-approval monitoring
• •Requires compliance with evolving regulations from agencies such as EMA, FDA, and WHO

Stringent and continually evolving regulatory requirements across major markets compel pharmaceutical companies to invest heavily in PV infrastructure and expertise. The growing complexity of the global drug pipeline, including biologics, cell therapies, and personalized medicines, introduces novel safety monitoring challenges that demand more sophisticated pharmacovigilance capabilities.

• •Regulatory mandates from EMA, FDA, and other agencies requiring comprehensive safety data collection and reporting
• •Rising volume of adverse event reports driven by an expanding global pharmaceutical pipeline and increased drug utilization
• •Growing trend among pharmaceutical companies to outsource PV functions to specialized vendors for cost efficiency and scalability

The market is broadly segmented by service type, including in-house operations, outsourced services, and software solutions for safety database management and signal detection. Geographically, North America holds the largest share, supported by the presence of major pharmaceutical companies, mature regulatory frameworks, and high outsourcing activity. Europe follows closely, driven by EMA regulations and a robust biopharmaceutical sector, while the Asia-Pacific region is emerging as a fast-growing market due to expanding drug development and evolving pharmacovigilance requirements in countries such as China and India.

• •North America leads in market share, supported by mature regulatory frameworks and a high concentration of pharma and biotech companies
• •Europe maintains a strong position due to EMA pharmacovigilance regulations and an established biopharmaceutical ecosystem
• •Asia-Pacific is a fast-growing region, fueled by rising drug development activity and improving PV regulatory standards

What are the recent trends and outlook?

The integration of artificial intelligence and machine learning for signal detection and case processing is transforming pharmacovigilance workflows, enabling faster identification of safety patterns across large datasets. The growing adoption of real-world evidence and real-world data sources, including electronic health records and patient registries, is reshaping how safety signals are monitored beyond traditional clinical trial and spontaneous reporting frameworks. Over the forecast period, the market's 9.51% growth trajectory will likely be sustained by continued regulatory tightening, the global expansion of drug safety requirements, and the ongoing shift toward technology-driven and outsourced PV solutions.

• •AI and machine learning are increasingly deployed to automate adverse event case processing, literature screening, and safety signal detection
• •Real-world evidence and real-world data from electronic health records and registries are expanding the data sources used for ongoing safety monitoring
• •Regulatory convergence efforts, such as ICH guidelines, are promoting global harmonization of PV standards and driving consistent market growth across regions